Seebri Breezhaler Adverse Reactions

Summary of the safety profile: The most common anticholinergic adverse reaction was dry mouth (2.4%). The majority of the reports of dry mouth were suspected to be related to the medicinal product and were mild, with none being severe.
The safety profile is further characterised by other symptoms related to the anticholinergic effects, including signs of urinary retention, which were uncommon. Gastrointestinal effects including gastroenteritis and dyspepsia were also observed. Adverse reactions related to local tolerability included throat irritation, nasopharyngitis, rhinitis and sinusitis.
Tabulated summary of adverse drug reactions: Adverse drug reactions reported during the first 6 months of 2 pooled pivotal phase III trials of 6 and 12 months duration are listed by MedDRA system organ class (see Table). Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to 1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). (See Table.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: In the pooled 6-month database the frequency of dry mouth was 2.2% vs 1.1%, of insomnia 1.0% vs 0.8%, and of gastroenteritis 1.4% vs 0.9%, for Seebri Breezhaler and placebo respectively.
Dry mouth was reported mainly during the first 4 weeks of treatment with a median duration of four weeks in the majority of patients. However in 40% of cases symptoms continued for the entire 6-month period. No new cases of dry mouth were reported in months 7-12.